Physician profile
Bindu Pathrose
NPI 1346436094
$1,963.90
in general payments reported to CMS, 2019-2025
19 companies · $33.34 in 2025
The $33.34 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $803 · 2021: $384 · 2022: $29.84 · 2023: $17.95 · 2024: $16.31 · 2025: $33.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $808.24 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $443.17 | 2019-2021 | |
| 180 Medical, INC. | $104.44 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $85.92 | 2019-2021 | |
| Fidia Pharma USA INC. | $79.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $72.65 | 2019 | |
| Depuy Synthes Sales INC. | $70.47 | 2019-2020 | |
| Abbvie INC. | $63.18 | 2022-2025 | |
| Biogen, INC. | $39.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.26 | 2023-2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $27.88 | 2021 | |
| Assertio Therapeutics, INC. | $20.98 | 2019 | |
| Ibsa Pharma INC. | $20.23 | 2021 | |
| Antares Pharma, INC. | $18.43 | 2020 | |
| Grt US Holding, INC. | $17.41 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $16.04 | 2020 | |
| Horizon Therapeutics Plc | $15.03 | 2021 | |
| Medtronic, INC. | $14.54 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Pathrose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.